{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=27", "query": { "condition": "DNA", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 3219, "total_pages": 322, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T23:15:53.597Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00040950", "title": "Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "agatolimod sodium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-03", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040950" }, { "nct_id": "NCT07115043", "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma (Skin)", "Renal Cell Carcinoma", "Merkel Cell Carcinoma", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Gastric Cancer/Gastroesophageal Junction Cancer", "High Grade Serous Ovarian Carcinoma" ], "interventions": [ { "name": "AZD6750", "type": "DRUG" }, { "name": "rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-07-29", "completion_date": "2029-10-02", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 6, "location_summary": "Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115043" }, { "nct_id": "NCT05811468", "title": "Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Transplant;Failure,Kidney", "Kidney Transplant", "Kidney Rejection Transplant" ], "interventions": [], "intervention_types": [], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 0, "start_date": "2023-09-26", "completion_date": "2025-05-30", "has_results": false, "last_update_posted_date": "2024-04-19", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05811468" }, { "nct_id": "NCT05838768", "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers" ], "interventions": [ { "name": "HRO761", "type": "DRUG" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 123, "start_date": "2023-06-27", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05838768" }, { "nct_id": "NCT02278536", "title": "Multiple Gestation Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Trisomy 13", "Trisomy 18", "Trisomy 21", "Sex Chromosome Abnormalities" ], "interventions": [], "intervention_types": [], "sponsor": "Natera, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 354, "start_date": "2013-03", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2019-08-26", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 6, "location_summary": "San Carlos, California • San Diego, California • New York, New York + 2 more", "locations": [ { "city": "San Carlos", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02278536" }, { "nct_id": "NCT00004192", "title": "Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Neutropenia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 60, "start_date": "2000-05-01", "completion_date": "2001-03-16", "has_results": false, "last_update_posted_date": "2023-12-27", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 3, "location_summary": "Los Angeles, California • Omaha, Nebraska • Cleveland, Ohio", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004192" }, { "nct_id": "NCT03436563", "title": "M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "High-Frequency Microsatellite Instability", "Metastatic Malignant Solid Neoplasm", "Rectal Adenocarcinoma", "Refractory Colorectal Carcinoma", "Stage IV Colon Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Anti-PD-L1/TGFbetaRII Fusion Protein M7824", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-03-07", "completion_date": "2023-08-08", "has_results": true, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436563" }, { "nct_id": "NCT03181789", "title": "Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "p24CE1/2 pDNA Vaccine", "type": "BIOLOGICAL" }, { "name": "p55^gag pDNA Vaccine", "type": "BIOLOGICAL" }, { "name": "IL-12 pDNA Adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 56, "start_date": "2017-10-18", "completion_date": "2020-04-29", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 3, "location_summary": "San Francisco, California • Decatur, Georgia • Cleveland, Ohio", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03181789" }, { "nct_id": "NCT00545987", "title": "Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "TriGrid™ Delivery System", "type": "DEVICE" }, { "name": "conventional intramuscular injection", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 40, "start_date": "2007-09", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2011-05-05", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00545987" }, { "nct_id": "NCT00001114", "title": "The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Interferon alfa-2b", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 90, "start_date": null, "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-30T23:15:53.597Z", "location_count": 12, "location_summary": "Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001114" } ] }